TIANJIN, China, Dec. 22, 2025 /PRNewswire/ — A news report from China Daily:

The 2025 “A Date with China” international media delegation concluded a three-day visit to Tianjin on Dec 17, getting a glimpse of the city’s development in preserving intangible cultural heritages, driving cutting-edge technological innovations, and advancing global vocational education.

To get a taste of Tianjin’s vibrant intangible cultural heritage, the group visited Tianjin Pingju Opera Theatre, Guangdong Guild Hall, and Xiaoliyuan Crosstalk Teahouse, where they donned traditional opera costumes, practiced kuaiban (rhythmic bamboo clappers), and experienced the art of “speaking, imitating, teasing, and singing”.

On Ancient Culture Street, Italian blogger Andrea stepped up to the griddle and tried his hand at making jianbing guozi (Chinese pancake wrap), joking, “You may have seen Italians make pizza, but this is probably the first time you’ve seen an Italian make jianbing guozi.”

The group also experienced Clay Figure Zhang and saw a shadow puppetry performance of Journey to the West. Bruno Falci, a reporter from TeleSUR, said that foreign journalists eagerly want to understand these art forms, and seized every chance to deeply explore Chinese culture.

The international media group also got a firsthand experience of Tianjin’s technological vitality at industrial parks and tech enterprises. American blogger Dante Munoz showed great interest in cutting-edge products, trying out foldable tablets, AI chat assistant, and intelligent health robots.

“Chinese products are high-tech and reliable; enterprises grasp global needs well,” Munoz said, adding that he’s looking forward to better localized products.

The intelligent upgrading of Tianjin Metro Line 1 also amazed global guests. A 360-degree vehicle exterior image detection system can identify loose screws and foreign objects, while an intelligent vehicle operation and maintenance system monitors door operations, driving modes, and traction braking levels. This human-machine collaboration enhances efficiency and reduces maintenance costs.

At the Luban Workshop Experience Museum, the delegation learned about China’s global vocational education achievements. They met four Egyptian students majoring in computer numerical control. Student Ibrahim Maher said studying there boosted his growth and that he hoped to bring Chinese skills back to Egypt.

Luban Workshop is a world-renowned cooperation brand created by Tianjin, introduced by Wang Juan, director of International Exchange and Cooperation Department at Tianjin Light Industry Vocational Technical College. Now, 36 Luban Workshops exist in 30 countries, training talents for local development like Egypt’s industrialization. “Luban Workshops teach practical skills,” Italian blogger Andrea said. “China now exports not just products but professional skills — remarkable.”

Source

TAIPEI, Dec. 22, 2025 /PRNewswire/ — MCB Group, a Taiwan-based global manufacturer of premium nutritional powder ingredients, has further streamlined its operations into a full CDMO private-label provider, showcasing a range of trend-driven branded ingredients and turnkey total solutions at SupplySide Global 2025, aimed at capturing growth in next year’s booming market.

The focus on MCB’s new ingredients reflects insights generated through its AI-powered market platform, revealing a clear shift: sports nutrition is rapidly becoming part of everyday nutrition. Consumers now prefer convenient delivery forms—such as drink sachets, coffee mixes, and ready-to-drink beverages —to incorporate nutrients like creatine, MCT powder, and plant-based proteins into their daily routines.

The global sports nutrition market is expected to reach USD 75 billion with CAGR of 7.5% by 2030, according to Grand View Research. The United States accounts for the largest share of global sports nutrition products, has seen incredible growth from creatine and plant-based protein are also appealing to mainstream consumers, with significant opportunity for brands in meal replacement and hydration (electrolytes) products.

Targeted Superior Ingredients Delivery for Sports Nutrition

As a long-established nutritional ingredients provider, MCB’s branded ingredients MCTsolutions™ Micro-encapsulated MCT Oil Powders, are already widely used in global sport and nutritional brands. As the result of operation integration, MCB leveraged ingredients for sport nutrition with advanced technology, redefining creatine and plant-based protein from ingredient to comprehensive private-label solutions.

“We analyze global scientific data alongside MCB market research through an AI-powered platform, which revealed that creatine monohydrate is the most extensively studied and trusted form of creatine. However generic creatine faces limitations like poor water solubility, low bioavailability, and common digestive discomfort.” said Dr.Joseph Chiu, VP of health ingredient for MCB Taiwan. “To address these limitations, we have implemented a Hydrogel Delivery System in our instant creatine monohydrate, CreHytine™.”

MCB’s branded instant creatine monohydrate CreHytine™ innovated with Hydrogel Delivery System, encapsulating creatine monohydrate within a gum-based hydrogel matrix and buffering alkaline mineral (magnesium), remain high creatine content and improved bioavailability, key advancements include:

• Exceptional Purity >98% Creatine Monohydrate
  With advanced encapsulation and buffering technology, CreHytine™ maintains an industry-leading 98% pure creatine monohydrate content, addressing a common trade-off between functionality and active concentration.
• Instant Dissolution Performance
  Engineered as an instant-type creatine monohydrate, CreHytine™ achieves complete dispersion in approximately 8 seconds, significantly outperforming standard micronized creatine and enhancing consumer convenience in ready-to-mix applications.
• Ultra-Fine Particle Engineering
  With a particle size refined to 200–300 mesh, CreHytine™ instant creatine monohydrate goes beyond generic micronized creatine, contributing to faster dissolution, improved mouthfeel, and superior formulation flexibility across powder blends, gummy, and functional beverages.
• pH Stability with Alkaline Mineral Buffering
  The integration of magnesium-based alkaline mineral buffering helps stabilize creatine monohydrate under acidic conditions, supporting improved bioavailability while also reducing common gastrointestinal discomfort associated with conventional creatine supplementation.

High-performance creatine monohydrate is one of the fastest-growing product categories within sports nutrition driven by consumers’ ongoing to shift toward active and healthier lifestyles. 

Private-Label Solutions from Sport Nutrition to Daily Life

With the expansion of its CDMO and private-label business, MCB is leveraging proprietary ingredients to develop a series of private-label solutions for dynamic sports nutrition market, including creatine, electrolytes(hydration), and protein products (especially pea protein, which contain essential amino acids and clean protein source free from allergens).

Daily Sports Nutrition Private-label Solution

MCB has designed a full range of sports nutrition private-label concepts for everyday supplementation, incorporate its branded ingredient CreHytine™ Instant Creatine Monohydrate, a hydrogel creatine monohydrate addressed all the challenges of genetic creatine:

• Creatine + Electrolytes (Hydration Formula): Integrating high-purity creatine monohydrate with a balanced electrolyte complex. The electrolytes private-label formula support hydration, recovery, and performance during training and daily physical activity.
• Pre-Workout Creatine Formula: Uses pH-corrected buffered creatine monohydrate for superior ATP metabolism, and vitamins with natural caffeine give the body more energy for daily life and exercise.
• Women Creatine Formula: Optimized creatine monohydrate for fast dissolution and clean taste, women creatine private label with added collagen to enhance skin and joint elasticity for modern active female.

Lifestyle Protein Supplementation Private label

The innovative protein collection integrates functional ingredients into daily diets, protein supplementation with benefits:

• Clear Protein Water: A light, refreshing, and cost-effective alternative to clear whey protein, formulated for modern, on-the-go consumers seeking convenient daily protein intake.
• Functional Meal Replacement: Powered by plant-based pea protein and enhanced with CollaGEM™-V Vegan Collagen Alternative, this formulation provides complete nutritional support tailored for vegan and vegetarian.

These private-label offering in a variety dosage, such as sachet, pouch and jar, transform MCB’s ingredient innovations into complete, market-ready formula for brands to enter booming market.

Catering Solutions for a Growing Market

MCB are coming off the high-speed periods of new private-label development, 3-5 innovative ingredients can be rapidly developed annually and turned into 130+ ODM market-ready formulas.

Throughout SupplySide Global 2025, MCB reaffirmed its position as a trusted global CDMO+ partner from ingredient to solution, capable of transforming complex scientific breakthroughs into commercially viable, consumer-ready supplement turnkey solutions. With a clear focus on next year’s growth markets—particularly daily sports nutrition (creatine), functional hydration, and lifestyle protein.

Source

SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ — WePlay, the global flagship social entertainment platform under WEJOY PTE. LTD., officially announced the launch of its “Let’s Celebrate Christmas Together” campaign, running from December 19 to 25. As a social platform beloved by Gen Z users aged 18–25 around the world, this year’s Christmas celebration introduces not only highly interactive features such as the Voice Room Red Envelope Rain and the Christmas Wish Plaza, but also a special charity initiative titled “Let’s Make a Wish for the Dogs!”

Entertainment Meets Philanthropy: Every Interaction Carries Warmth

In the “Let’s Make a Wish for the Dogs!” charity segment, users can accumulate Warmth Points by sending themed gifts or purchasing lottery tokens. The collective kindness of the entire community contributes to a growing progress bar. Each time the bar reaches a new milestone, WePlay will donate additional supplies to City Without Stray Dogs.

The campaign aims to deliver a total of 615 kg of prescription dog food and 50 electronic training whistles, which will support better nutrition and behavioral training for rescued dogs—helping them adapt to social environments and increasing their chances of adoption.

Brand Vision: Bridging Virtual Interaction with Real-World Kindness

WePlay remains committed to its mission of “Making the world better through interaction.” The platform not only provides young people with a vibrant social playground, but also aims to bridge the passion of the virtual world with real-world social responsibility.

Jingci Zhao , Head of WePlay Korea, stated:
“The heart of WePlay’s charity work lies in using the warmth of social interaction to transmit the power of life. Through this Christmas initiative, we hope young users can feel that WePlay is not only a place to make friends and have fun, but also a space where simple interactions can come together to make a real-world impact. Every bag of prescription food and every training whistle represents our users’ love and respect for life.”

About WePlay

WePlay is the flagship social entertainment platform under WEJOY PTE. LTD., headquartered in Singapore. Featuring popular titles such as Space Werewolf, Guess My Drawing, and Mic Grab, WePlay aims to create a dynamic digital space that blends games, social interaction, and entertainment—helping young users connect effortlessly and build meaningful friendships.

Media Contact

Company: WEJOY PTE. LTD.
Contact: Peinan Qi
Email: qipeinan@wejoysg.com 
WePlay Website: https://weplayapp.com/

Source

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to:

• TLX591-CDx (Illuccix® in approved jurisdictions, ⁶⁸Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.
• TLX101-CDx (Pixclara®^[1], ¹⁸F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, finalizing NDA resubmission and expect to provide a further near-term update on FDA acceptance of the file.
• TLX250-CDx (Zircaix®^[1], ⁸⁹Zr-DFO-girentuximab), PET imaging candidate for ccRCC: Positive Type A meeting held with the FDA to align on remediation of CMC deficiencies identified in the CRL.

Further details on each of these updates is provided below.

Illuccix China Phase 3 Registration Study

Telix is pleased to announce positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of ⁶⁸Ga-PSMA-11) for prostate cancer imaging in Chinese patients. The Illuccix China^[2] trial met its primary endpoint of patient-level positive predictive value (PPV) for the detection of tumors in patients with biochemical recurrence (BCR) of prostate cancer following prior radical prostatectomy or radiation therapy. The study confirms that the clinical experience of TLX591-CDx PSMA-PET^[3] imaging in Chinese patients is comparable to that observed in patients studied elsewhere.

Illuccix China is a Phase 3 prospective, open-label, single-arm, multicenter study conducted in collaboration with Telix’s strategic commercial partner for the Greater China region, Grand Pharmaceutical Group Limited (Grand Pharma). The study in 140 patients delivered a strong result for the primary endpoint, with an overall patient-level PPV of 94.8% for the detection of tumors with TLX591-CDx (95% confidence interval [CI]: 85.9%, 98.2%), with the lower bound of the 95% CI (85.9%). The region-level PPV was 100.0% in the prostate bed and in the extra-pelvic soft tissue, lymph nodes, and organ metastases (non-bone); 94.7% in the pelvic region outside of the prostate bed, including lymph nodes; and 87.0% in bone metastases.

In the study, patients with suspected BCR were stratified into groups according to their baseline prostate specific antigen (PSA) levels. TLX591-CDx PSMA-PET imaging demonstrated high PPV in all patient groups, including at very low baseline PSA levels.

More than two-thirds (67.2%) of patients experienced a change in their treatment plan as a consequence of TLX591-CDx PSMA-PET imaging compared with the initial plan at baseline. This outcome confirms that PSMA-PET imaging with TLX591-CDx had a meaningful impact on clinical decision-making in Chinese patients, potentially leading to improved treatment strategies for participants with BCR. Final data from the study will be submitted for peer-reviewed publication.

Dr. David N. Cade, Group Chief Medical Officer, Telix, commented, “This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability. These compelling data will enable Telix and our partner Grand Pharma to submit a New Drug Application for Illuccix in China, a strategically important market.”

In China, more than 134,000 men were diagnosed with prostate cancer in 2022^[4], increasing by approximately 6% each year^[5]. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to surpass 1,600 by the end of 2025^[6], compared with 133 in 2010^[7].

FDA Resubmission Update: TLX101-CDx

Telix advises that its New Drug Application (NDA) resubmission for TLX101-CDx, (Pixclara®^[1], ¹⁸F-floretyrosine) to the United States (U.S.) Food and Drug Administration (FDA), is progressing well. The Company has had collaborative interactions with the FDA around providing additional clinical data and a revised statistical analysis plan.

Following a productive Type A meeting to review the basis of the Complete Response Letter (CRL)^[8], Telix is currently finalizing its package for resubmission. The Company will provide a further near-term update when the resubmission has been filed and accepted by the FDA. The approved Expanded Access Program (EAP)^[9] remains active for TLX101-CDx, reflective of Telix’s commitment to serving patients.

FDA Resubmission Update: TLX250-CDx

Telix has recently participated in a Type A meeting to discuss the CRL it received following review of the Biologics License Application (BLA)^[10] for TLX250-CDx (Zircaix®^[1], ⁸⁹Zr-DFO-girentuximab). Telix believes it has reached alignment with the FDA on the remediation of identified deficiencies regarding the product’s chemistry, manufacturing, and controls (CMC) package, which formed the substantive basis of the CRL.

The FDA has collaboratively granted Telix an additional meeting in January to review Telix’s plan for the additional data requested to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial^[11] and the scaled-up manufacturing process intended for commercial use. Telix will provide a further update following receipt of the official FDA meeting minutes of both Type A meetings. The approved Expanded Access Program (EAP)^[12] remains active for TLX250-CDx, reflective of Telix’s commitment to serving patients.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA^[13].

TLX101-CDx is Telix’s PET imaging candidate for glioma, a rare and life-threatening brain cancer. TLX250-CDx is Telix’s PET imaging candidate for the diagnosis and characterization of clear cell renal cell carcinoma, the most common kidney cancer subtype. TLX101-CDx and TLX250-CDx have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-CDx and the planned BLA resubmission for TLX250-CDx, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

Source

HONG KONG, Dec. 21, 2025 /PRNewswire/ — Dreame Technology, a global tech company dedicated to innovation in smart home appliances, officially opened its first offline flagship store in Hong Kong. Since entering the Hong Kong market, Dreame has been steadily strengthening its local presence. The opening of this flagship store marks a significant milestone in the brand’s expansion within the region.

Located in the Tsim Sha Tsui District at Mira Place, the new store marks the first public showcase of Dreame’s two latest flagship stick vacuums — the S50 Station and V50 — while also offering an exclusive early hands-on trial of the H16 Pro Steam. Visitors can explore Dreame’s full range of smart cleaning and personal care solutions, including the Aqua 10 Pro Track and Aqua10 Roller robot vacuums, the Pocket Uni global-voltage high-speed hair dryer, and more. In addition, Dreame’s latest air purifier, the PM20, makes its official debut in Hong Kong.

New Flagship Stick Vacuum Debut: Introducing the Dreame’s First Tangle-Cut™ Motorized Dual Blades Technology

At the event, Dreame unveiled two new stick vacuums — the V50 and the S50 Station. Both models are equipped with Dreame’s breakthrough Tangle-Cut™ Motorized Dual Blades Technology, capable of cutting up to 210,000 strands of human or pet hair in a single cleaning session, ensuring truly zero tangling.

Utilizing aerospace-grade, dual-layer titanium-coated blades, the system features approximately 200 high-density serrated blades that rapidly intersect and shear hair at speeds of up to 2,000 cuts per minute, significantly enhancing cutting efficiency. This innovation effectively addresses the long-standing issue of hair tangling found in traditional roller brushes, enabling both pet-owning households and users with long hair to enjoy a truly hands-free cleaning experience.

Equipped with a 130,000 RPM high-speed motor delivering 210AW suction power, both models effectively remove fine dust and dirt from floor crevices. The 140° wide-angle illumination reveals hidden dust, making cleaning even more thorough. Users can also upgrade with the AquaCycle™ 2.0 Suction-Washing Head, which uses electrolyzed water for sterilization and Dreame’s unique “Wash–Suction–Separation” process to efficiently handle both wet and dry messes.

S50 Station: Tangle-Cut™ Motorized Dual Blades with Auto Empty

As Dreame’s newest premium auto-empty stick vacuum in Hong Kong, the S50 Station features a multi-functional dust removal Hub that automatically performs dust collection and charging after each cleaning session. The 3L antibacterial dust bag, offering up to 100 days of long-term dust storage, significantly reduces maintenance while ensuring a hygienic home environment.

To ensure clean air out, the S50 Station is equipped with a multi-layer filtration system that delivers 99.99% whole-machine filtration efficiency, capturing particles as small as 0.1 µm. In addition, the HEPA H14 filter effectively traps bacteria and viruses, achieving a remarkable 99.99% filtration efficiency*. The Ultra Mode further enhances antibacterial performance before purified air is released back into the room. The smart indicator lighting clearly displays dust collection status, sterilization mode, and vacuum placement at a glance. With its high level of automation, hygiene, and efficiency, the S50 Station showcases Dreame’s leadership in high-end cleaning technology, delivering a smarter and healthier cleaning experience for Hong Kong households.

V50: Tangle-Cut™ Motorized Dual Blades with 1.6kg Lightweight

Designed for flexibility and ease of use, the V50 features an ultra-lightweight form factor paired with Tangle-Cut™ Motorized Dual Blades. Without the need for a base station, it is ideal for quick cleanups and everyday touch-ups, especially in small apartments or households that require frequent spot cleaning. With enhanced maneuverability and strong value for money, the V50 stands out as an excellent choice for users seeking a lightweight and versatile vacuum solution.

H16 Pro Steam: Dual-arm powered, 200°C Steam-enhanced clean

Now available for early experience at the flagship store and officially launching across Hong Kong on December 22, 2025, the H16 Pro Steam features industry-leading SaunaClean™ 200°C Steam Wash, combined with a 3000 mg/min high steam spraying to effectively dissolve grease, tackle stubborn stains, and achieve up to 99.9999% sterilization. Paired with ThermoRinse™ 90°C Hot Water Mopping, its dual-heat source floor washing is particularly suited for kitchens and dining areas with heavy grease buildup. The world’s first Dual-Arm Robotic AI DescendReach system delivers gap-free cleaning, zero water residue, and 100% tough stain removal, effectively minimizing cleaning blind spots and enhancing overall coverage and efficiency.

With enhanced true steam and hot water washing, the H16 Pro Steam provides faster, more effective, and more reliable home cleaning results.

Aqua 10 Pro Track: Mopping with 45°C Fresh Hot Water

Over the past two years, Dreame robot vacuums have redefined the market with industry-first innovations such as Robotic Retractable Legs, Dual Flex Arm Technology, VersaLift™ Navigation Technology, and advanced intelligent algorithms. These technologies have not only improved user experience but also earned Dreame the #1 market share in 18 countries worldwide. This year, Dreame takes robot vacuuming to the next level with its innovative Aqua 10 Pro Track and Aqua10 Roller, part of the fresh water cleaning series.

The Aqua 10 Pro Track, Dreame’s most advanced robot vacuum to date, introduces the industry’s first 45°C TrackSync™ Constant Hot Water Mopping, allowing the mop to clean and self-clean simultaneously with every rotation — solving the common problem of “the more you mop, the dirtier it gets.” Equipped with intelligent dirt detection and an extended track design for edge cleaning, it delivers deep cleaning performance even on heavy stains, oil spills, and tile grout. Beyond mopping, Aqua 10 Pro Track features 25,000Pa powerful suction, HyperStream™ Detangling DuoBrush, and Dual Flex Arm Technology for a comprehensive cleaning performance. OmniSight™ Navigation & Obstacle Avoidance and ProLeap™ 6cm Obstacle Cleaning ensure smooth movement across thresholds and carpets. The all-in-one smart base station takes the cleaning experience to a whole new level of automation. From ThermoHub™ 100°C Mop Self-Cleaning and Mop and Dust Bag Auto-Drying to UV sterilization, Auto Solution Refilling, and 100 Days Auto-Empty, it handles all maintenance in a single step — delivering a more convenient, hygienic, and intelligent whole-home cleaning solution.

Pocket Uni: The Ultimate “Travel Anywhere” Styling Tool

A Hong Kong fan favorite, the globally compatible 100–240V foldable high-speed hair dryer Pocket Uni has sold over 10,000 units in Hong Kong since launch. Weighing only 330g, its triple-fold design makes it ideal for travel and business trips. Powered by a 110,000 RPM high-speed motor, it delivers fast drying and styling with strong, stable airflow. Plasma Ion Concentration reduces frizz and enhances hair shine, while the upgraded SmartVolt™ Global Voltage Compatible ensures seamless use worldwide. The compact hair dryer also includes a Unfrizz Nozzle and Curling Barrels for versatile styling anytime, anywhere.

PM20：Dreame Hong Kong’s First All-in-One Smart Air Purifier

Dreame officially launches its first air purifier in Hong Kong, the PM20, which combines cooling and heating with intelligent air purification. In summer, it rapidly circulates air to deliver a refreshing flow of cool, clean air. In winter, it heats up in just three seconds, instantly filling the home with comfortable warmth even during cold weather.

Powered by jet airflow technology and a dual-way air outlet design that directs airflow both upward and forward, the PM20 delivers far-reaching airflow of up to 10 meters and a CADR of 400 m³/h, ensuring more uniform air circulation and comprehensive purification across the home.

The PM20 is equipped with a 4-Layer Filtration System, featuring an high-efficiency composite filter, an activated carbon layer, and an MnO₂ catalytic decomposition filter. Working together, the system effectively captures ultra-fine particles and allergens while continuously breaking down formaldehyde and other harmful gases, helping to maintain cleaner, healthier indoor air without the need for frequent filter replacement. Combined with intelligent environmental sensing and App connectivity, the PM20 allows users to monitor indoor air quality in real time, delivering a smart, hygienic, and comfortable living environment for the entire home.

Grand Opening Promotions

To celebrate the launch, Dreame will offer limited-time discounts, exclusive member benefits, and an opening raffle.

About Dreame

Established in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home appliances with the vision to empower lives through technology. Follow us on Facebook and Instagram.

For more information, visit dreametech.com.hk

Source

• The iconic Yas Marina Circuit included in Gran Turismo 7, for PlayStation 4 and 5, offering global players the chance to explore and race the emirate’s flagship track
• Announcement made during the Gran Turismo World Series 2025 World Finals in Fukuoka, Japan

ABU DHABI, UAE, Dec. 20, 2025 /PRNewswire/ — For the first time in the Middle East, Abu Dhabi will host the Gran Turismo World Series 2026 opening event, scheduled for 28^th of March 2026 at the Space42 Arena. The landmark event will bring together the world’s top Gran Turismo drivers to compete in an elite live championship, engaging fans in the emirate and highlighting Abu Dhabi’s esports capabilities to millions worldwide.

For the first time in the Middle East, Abu Dhabi will host the Gran Turismo World Series 2026 opening event, scheduled for the 28th of March 2026 at the Space42 Arena.

The announcement was made during the Gran Turismo World Series 2025 World Finals at the Fukuoka International Congress Centre in Japan, where H.E. Saeed Al Fazari, Executive Director of Strategic Affairs at the Department of Culture and Tourism – Abu Dhabi (DCT Abu Dhabi), took the stage to share the news.

The Gran Turismo World Series 2026 opening event is organised by Polyphony Digital Inc, a subsidiary of Sony Interactive Entertainment, the developer and publisher of the Gran Turismo series, and Abu Dhabi Gaming, an initiative led by DCT Abu Dhabi that coordinates efforts to transform the emirate into a global gaming hub.

At the Gran Turismo World Series 2025 World Finals, held at the Fukuoka International Congress Centre in Japan, H.E. Saeed Al Fazari, Executive Director of Strategic Affairs at the Department of Culture and Tourism – Abu Dhabi, and Kazunori Yamauchi, Gran Turismo series producer, announce that Abu Dhabi will host the Gran Turismo World Series 2026 opening event, for the first time in the Middle East.

H.E. Al Fazari said: “Hosting the Gran Turismo World Series opener is a proud moment for Abu Dhabi and the wider MENA region, reflecting our ambition to be a destination where possibilities are limitless. It marks a significant milestone for our esports and motorsport sectors, bringing elite global competition to the emirate and showcasing Abu Dhabi’s proven capability to deliver world-leading esports and motorsport experiences. Abu Dhabi continues to offer a secure, future-ready environment for businesses, investors and talent, supporting our vision to become a global hub for innovation, entertainment, gaming and motorsport.” 

The Gran Turismo World Series is an annual competition to determine the world’s best Gran Turismo player, comprising online qualifiers open to all players and live World Series events in which top racers travel to iconic destinations worldwide to compete.

Kazunori Yamauchi, Gran Turismo series producer., said: “We are thrilled to see Abu Dhabi host the 2026 Gran Turismo World Series opener in March 2026, marking the first time the event will be held in the Middle East. This is a historic milestone for our championship and a testament to the region’s growing presence in global motorsport and esports. Additionally, we are delighted that Yas Marina Circuit, one of the world’s most distinctive motorsport venues, is now available in Gran Turismo 7. Our aim has always been to connect players with the thrill and heritage of racing, and Yas Marina offers a unique experience that will resonate with motorsport fans and the gaming community worldwide.”

The Yas Marina Circuit’s inclusion in Gran Turismo 7 further extends Abu Dhabi’s motorsport legacy into the digital arena, creating new opportunities for global audiences to connect with the emirate’s culture of competitive excellence.

“This announcement marks an exciting moment for motorsports and esports fans in this region and the world, and positions Abu Dhabi Gaming at the forefront of the global sim racing conversation, reflecting our role as a connector of world-class partners and opportunities,” said Marcos Muller‑Habig, Sector Enablement Director at Abu Dhabi Gaming. “As we continue to drive the emirate’s vision to become a premier global destination and a leading hub for the gaming and esports industries, events like the Gran Turismo World Series 2026 become catalysts for growth and a key milestone in our journey to build an ecosystem that empowers talent, attracts partnerships and accelerates business development.”

Gran Turismo, developed by Polyphony Digital Inc., a subsidiary of Sony Interactive Entertainment, is regarded as one of the most visually and dynamically accurate driving simulators available, recently surpassing 100 million sales of the series.

For more information about Gran Turismo World Series 2026 Opener in Abu Dhabi and tickets, please visit www.ticketmaster.ae/event/1588346815.

For more information about Abu Dhabi Gaming, follow Abu Dhabi Gaming on Instagram, YouTube and Twitch.

Source